nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoversetamide—Skin disorder—Sorafenib—thyroid cancer	0.00214	0.00214	CcSEcCtD
Gadoversetamide—Neck pain—Doxorubicin—thyroid cancer	0.00214	0.00214	CcSEcCtD
Gadoversetamide—Anorexia—Sorafenib—thyroid cancer	0.0021	0.0021	CcSEcCtD
Gadoversetamide—Injection site reaction—Doxorubicin—thyroid cancer	0.0021	0.0021	CcSEcCtD
Gadoversetamide—Cramps of lower extremities—Epirubicin—thyroid cancer	0.0021	0.0021	CcSEcCtD
Gadoversetamide—Vomiting—Vandetanib—thyroid cancer	0.00208	0.00208	CcSEcCtD
Gadoversetamide—Eructation—Doxorubicin—thyroid cancer	0.00208	0.00208	CcSEcCtD
Gadoversetamide—Ecchymosis—Epirubicin—thyroid cancer	0.00207	0.00207	CcSEcCtD
Gadoversetamide—Melaena—Doxorubicin—thyroid cancer	0.00207	0.00207	CcSEcCtD
Gadoversetamide—Rash—Vandetanib—thyroid cancer	0.00206	0.00206	CcSEcCtD
Gadoversetamide—Dermatitis—Vandetanib—thyroid cancer	0.00206	0.00206	CcSEcCtD
Gadoversetamide—Salivary hypersecretion—Doxorubicin—thyroid cancer	0.00205	0.00205	CcSEcCtD
Gadoversetamide—Headache—Vandetanib—thyroid cancer	0.00205	0.00205	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00201	0.00201	CcSEcCtD
Gadoversetamide—Hypertonia—Epirubicin—thyroid cancer	0.002	0.002	CcSEcCtD
Gadoversetamide—Dyspnoea—Sorafenib—thyroid cancer	0.00197	0.00197	CcSEcCtD
Gadoversetamide—Nausea—Vandetanib—thyroid cancer	0.00194	0.00194	CcSEcCtD
Gadoversetamide—Cramps of lower extremities—Doxorubicin—thyroid cancer	0.00194	0.00194	CcSEcCtD
Gadoversetamide—Dyspepsia—Sorafenib—thyroid cancer	0.00194	0.00194	CcSEcCtD
Gadoversetamide—Decreased appetite—Sorafenib—thyroid cancer	0.00192	0.00192	CcSEcCtD
Gadoversetamide—Thrombophlebitis—Epirubicin—thyroid cancer	0.00192	0.00192	CcSEcCtD
Gadoversetamide—Ecchymosis—Doxorubicin—thyroid cancer	0.00191	0.00191	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.0019	0.0019	CcSEcCtD
Gadoversetamide—Fatigue—Sorafenib—thyroid cancer	0.0019	0.0019	CcSEcCtD
Gadoversetamide—Pain—Sorafenib—thyroid cancer	0.00189	0.00189	CcSEcCtD
Gadoversetamide—Constipation—Sorafenib—thyroid cancer	0.00189	0.00189	CcSEcCtD
Gadoversetamide—Hypertonia—Doxorubicin—thyroid cancer	0.00185	0.00185	CcSEcCtD
Gadoversetamide—Eye pain—Epirubicin—thyroid cancer	0.00184	0.00184	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Sorafenib—thyroid cancer	0.0018	0.0018	CcSEcCtD
Gadoversetamide—Thrombophlebitis—Doxorubicin—thyroid cancer	0.00177	0.00177	CcSEcCtD
Gadoversetamide—Increased appetite—Epirubicin—thyroid cancer	0.00177	0.00177	CcSEcCtD
Gadoversetamide—Urticaria—Sorafenib—thyroid cancer	0.00175	0.00175	CcSEcCtD
Gadoversetamide—Body temperature increased—Sorafenib—thyroid cancer	0.00174	0.00174	CcSEcCtD
Gadoversetamide—Abdominal pain—Sorafenib—thyroid cancer	0.00174	0.00174	CcSEcCtD
Gadoversetamide—Eye pain—Doxorubicin—thyroid cancer	0.0017	0.0017	CcSEcCtD
Gadoversetamide—Hypoglycaemia—Epirubicin—thyroid cancer	0.0017	0.0017	CcSEcCtD
Gadoversetamide—Hyponatraemia—Epirubicin—thyroid cancer	0.00167	0.00167	CcSEcCtD
Gadoversetamide—Diplopia—Epirubicin—thyroid cancer	0.00166	0.00166	CcSEcCtD
Gadoversetamide—Increased appetite—Doxorubicin—thyroid cancer	0.00163	0.00163	CcSEcCtD
Gadoversetamide—Hypersensitivity—Sorafenib—thyroid cancer	0.00163	0.00163	CcSEcCtD
Gadoversetamide—Face oedema—Epirubicin—thyroid cancer	0.0016	0.0016	CcSEcCtD
Gadoversetamide—Asthenia—Sorafenib—thyroid cancer	0.00158	0.00158	CcSEcCtD
Gadoversetamide—Hypoglycaemia—Doxorubicin—thyroid cancer	0.00157	0.00157	CcSEcCtD
Gadoversetamide—Pruritus—Sorafenib—thyroid cancer	0.00156	0.00156	CcSEcCtD
Gadoversetamide—Blood creatinine increased—Epirubicin—thyroid cancer	0.00155	0.00155	CcSEcCtD
Gadoversetamide—Hyponatraemia—Doxorubicin—thyroid cancer	0.00154	0.00154	CcSEcCtD
Gadoversetamide—Diplopia—Doxorubicin—thyroid cancer	0.00153	0.00153	CcSEcCtD
Gadoversetamide—Dry skin—Epirubicin—thyroid cancer	0.00152	0.00152	CcSEcCtD
Gadoversetamide—Diarrhoea—Sorafenib—thyroid cancer	0.00151	0.00151	CcSEcCtD
Gadoversetamide—Nasopharyngitis—Epirubicin—thyroid cancer	0.00148	0.00148	CcSEcCtD
Gadoversetamide—Face oedema—Doxorubicin—thyroid cancer	0.00148	0.00148	CcSEcCtD
Gadoversetamide—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.00146	0.00146	CcSEcCtD
Gadoversetamide—Muscular weakness—Epirubicin—thyroid cancer	0.00146	0.00146	CcSEcCtD
Gadoversetamide—Dizziness—Sorafenib—thyroid cancer	0.00146	0.00146	CcSEcCtD
Gadoversetamide—Blood creatinine increased—Doxorubicin—thyroid cancer	0.00144	0.00144	CcSEcCtD
Gadoversetamide—Asthma—Epirubicin—thyroid cancer	0.00143	0.00143	CcSEcCtD
Gadoversetamide—Influenza—Epirubicin—thyroid cancer	0.00143	0.00143	CcSEcCtD
Gadoversetamide—Dysphagia—Epirubicin—thyroid cancer	0.00143	0.00143	CcSEcCtD
Gadoversetamide—Dry skin—Doxorubicin—thyroid cancer	0.00141	0.00141	CcSEcCtD
Gadoversetamide—Vomiting—Sorafenib—thyroid cancer	0.0014	0.0014	CcSEcCtD
Gadoversetamide—Rash—Sorafenib—thyroid cancer	0.00139	0.00139	CcSEcCtD
Gadoversetamide—Dermatitis—Sorafenib—thyroid cancer	0.00139	0.00139	CcSEcCtD
Gadoversetamide—Headache—Sorafenib—thyroid cancer	0.00138	0.00138	CcSEcCtD
Gadoversetamide—Nasopharyngitis—Doxorubicin—thyroid cancer	0.00137	0.00137	CcSEcCtD
Gadoversetamide—Muscular weakness—Doxorubicin—thyroid cancer	0.00135	0.00135	CcSEcCtD
Gadoversetamide—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.00135	0.00135	CcSEcCtD
Gadoversetamide—Dysuria—Epirubicin—thyroid cancer	0.00134	0.00134	CcSEcCtD
Gadoversetamide—Influenza—Doxorubicin—thyroid cancer	0.00133	0.00133	CcSEcCtD
Gadoversetamide—Dysphagia—Doxorubicin—thyroid cancer	0.00133	0.00133	CcSEcCtD
Gadoversetamide—Asthma—Doxorubicin—thyroid cancer	0.00133	0.00133	CcSEcCtD
Gadoversetamide—Nausea—Sorafenib—thyroid cancer	0.00131	0.00131	CcSEcCtD
Gadoversetamide—Hyperglycaemia—Epirubicin—thyroid cancer	0.00129	0.00129	CcSEcCtD
Gadoversetamide—Pneumonia—Epirubicin—thyroid cancer	0.00129	0.00129	CcSEcCtD
Gadoversetamide—Conjunctivitis—Epirubicin—thyroid cancer	0.00124	0.00124	CcSEcCtD
Gadoversetamide—Urinary tract infection—Epirubicin—thyroid cancer	0.00124	0.00124	CcSEcCtD
Gadoversetamide—Dysuria—Doxorubicin—thyroid cancer	0.00124	0.00124	CcSEcCtD
Gadoversetamide—Haematuria—Epirubicin—thyroid cancer	0.00122	0.00122	CcSEcCtD
Gadoversetamide—Epistaxis—Epirubicin—thyroid cancer	0.00121	0.00121	CcSEcCtD
Gadoversetamide—Sinusitis—Epirubicin—thyroid cancer	0.0012	0.0012	CcSEcCtD
Gadoversetamide—Hyperglycaemia—Doxorubicin—thyroid cancer	0.0012	0.0012	CcSEcCtD
Gadoversetamide—Pneumonia—Doxorubicin—thyroid cancer	0.00119	0.00119	CcSEcCtD
Gadoversetamide—Haemoglobin—Epirubicin—thyroid cancer	0.00115	0.00115	CcSEcCtD
Gadoversetamide—Rhinitis—Epirubicin—thyroid cancer	0.00115	0.00115	CcSEcCtD
Gadoversetamide—Conjunctivitis—Doxorubicin—thyroid cancer	0.00115	0.00115	CcSEcCtD
Gadoversetamide—Urinary tract infection—Doxorubicin—thyroid cancer	0.00115	0.00115	CcSEcCtD
Gadoversetamide—Haemorrhage—Epirubicin—thyroid cancer	0.00115	0.00115	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Epirubicin—thyroid cancer	0.00114	0.00114	CcSEcCtD
Gadoversetamide—Pharyngitis—Epirubicin—thyroid cancer	0.00114	0.00114	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Epirubicin—thyroid cancer	0.00113	0.00113	CcSEcCtD
Gadoversetamide—Oedema peripheral—Epirubicin—thyroid cancer	0.00113	0.00113	CcSEcCtD
Gadoversetamide—Haematuria—Doxorubicin—thyroid cancer	0.00113	0.00113	CcSEcCtD
Gadoversetamide—Urethral disorder—Epirubicin—thyroid cancer	0.00112	0.00112	CcSEcCtD
Gadoversetamide—Epistaxis—Doxorubicin—thyroid cancer	0.00112	0.00112	CcSEcCtD
Gadoversetamide—Sinusitis—Doxorubicin—thyroid cancer	0.00111	0.00111	CcSEcCtD
Gadoversetamide—Erythema multiforme—Epirubicin—thyroid cancer	0.00108	0.00108	CcSEcCtD
Gadoversetamide—Eye disorder—Epirubicin—thyroid cancer	0.00107	0.00107	CcSEcCtD
Gadoversetamide—Tinnitus—Epirubicin—thyroid cancer	0.00107	0.00107	CcSEcCtD
Gadoversetamide—Haemoglobin—Doxorubicin—thyroid cancer	0.00107	0.00107	CcSEcCtD
Gadoversetamide—Cardiac disorder—Epirubicin—thyroid cancer	0.00106	0.00106	CcSEcCtD
Gadoversetamide—Flushing—Epirubicin—thyroid cancer	0.00106	0.00106	CcSEcCtD
Gadoversetamide—Rhinitis—Doxorubicin—thyroid cancer	0.00106	0.00106	CcSEcCtD
Gadoversetamide—Haemorrhage—Doxorubicin—thyroid cancer	0.00106	0.00106	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00106	0.00106	CcSEcCtD
Gadoversetamide—Pharyngitis—Doxorubicin—thyroid cancer	0.00105	0.00105	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00105	0.00105	CcSEcCtD
Gadoversetamide—Oedema peripheral—Doxorubicin—thyroid cancer	0.00105	0.00105	CcSEcCtD
Gadoversetamide—Angiopathy—Epirubicin—thyroid cancer	0.00104	0.00104	CcSEcCtD
Gadoversetamide—Urethral disorder—Doxorubicin—thyroid cancer	0.00104	0.00104	CcSEcCtD
Gadoversetamide—Immune system disorder—Epirubicin—thyroid cancer	0.00104	0.00104	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Epirubicin—thyroid cancer	0.00103	0.00103	CcSEcCtD
Gadoversetamide—Chills—Epirubicin—thyroid cancer	0.00103	0.00103	CcSEcCtD
Gadoversetamide—Arrhythmia—Epirubicin—thyroid cancer	0.00103	0.00103	CcSEcCtD
Gadoversetamide—Mental disorder—Epirubicin—thyroid cancer	0.00101	0.00101	CcSEcCtD
Gadoversetamide—Erythema multiforme—Doxorubicin—thyroid cancer	0.001	0.001	CcSEcCtD
Gadoversetamide—Erythema—Epirubicin—thyroid cancer	0.000999	0.000999	CcSEcCtD
Gadoversetamide—Malnutrition—Epirubicin—thyroid cancer	0.000999	0.000999	CcSEcCtD
Gadoversetamide—Eye disorder—Doxorubicin—thyroid cancer	0.000992	0.000992	CcSEcCtD
Gadoversetamide—Tinnitus—Doxorubicin—thyroid cancer	0.00099	0.00099	CcSEcCtD
Gadoversetamide—Flushing—Doxorubicin—thyroid cancer	0.000985	0.000985	CcSEcCtD
Gadoversetamide—Cardiac disorder—Doxorubicin—thyroid cancer	0.000985	0.000985	CcSEcCtD
Gadoversetamide—Flatulence—Epirubicin—thyroid cancer	0.000984	0.000984	CcSEcCtD
Gadoversetamide—Tension—Epirubicin—thyroid cancer	0.00098	0.00098	CcSEcCtD
Gadoversetamide—Dysgeusia—Epirubicin—thyroid cancer	0.000978	0.000978	CcSEcCtD
Gadoversetamide—Nervousness—Epirubicin—thyroid cancer	0.00097	0.00097	CcSEcCtD
Gadoversetamide—Back pain—Epirubicin—thyroid cancer	0.000966	0.000966	CcSEcCtD
Gadoversetamide—Angiopathy—Doxorubicin—thyroid cancer	0.000963	0.000963	CcSEcCtD
Gadoversetamide—Muscle spasms—Epirubicin—thyroid cancer	0.00096	0.00096	CcSEcCtD
Gadoversetamide—Immune system disorder—Doxorubicin—thyroid cancer	0.000959	0.000959	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000957	0.000957	CcSEcCtD
Gadoversetamide—Chills—Doxorubicin—thyroid cancer	0.000953	0.000953	CcSEcCtD
Gadoversetamide—Arrhythmia—Doxorubicin—thyroid cancer	0.000949	0.000949	CcSEcCtD
Gadoversetamide—Vision blurred—Epirubicin—thyroid cancer	0.000941	0.000941	CcSEcCtD
Gadoversetamide—Mental disorder—Doxorubicin—thyroid cancer	0.00093	0.00093	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Epirubicin—thyroid cancer	0.000927	0.000927	CcSEcCtD
Gadoversetamide—Erythema—Doxorubicin—thyroid cancer	0.000924	0.000924	CcSEcCtD
Gadoversetamide—Malnutrition—Doxorubicin—thyroid cancer	0.000924	0.000924	CcSEcCtD
Gadoversetamide—Agitation—Epirubicin—thyroid cancer	0.000918	0.000918	CcSEcCtD
Gadoversetamide—Flatulence—Doxorubicin—thyroid cancer	0.000911	0.000911	CcSEcCtD
Gadoversetamide—Tension—Doxorubicin—thyroid cancer	0.000907	0.000907	CcSEcCtD
Gadoversetamide—Dysgeusia—Doxorubicin—thyroid cancer	0.000905	0.000905	CcSEcCtD
Gadoversetamide—Malaise—Epirubicin—thyroid cancer	0.000901	0.000901	CcSEcCtD
Gadoversetamide—Nervousness—Doxorubicin—thyroid cancer	0.000898	0.000898	CcSEcCtD
Gadoversetamide—Vertigo—Epirubicin—thyroid cancer	0.000897	0.000897	CcSEcCtD
Gadoversetamide—Syncope—Epirubicin—thyroid cancer	0.000896	0.000896	CcSEcCtD
Gadoversetamide—Back pain—Doxorubicin—thyroid cancer	0.000894	0.000894	CcSEcCtD
Gadoversetamide—Muscle spasms—Doxorubicin—thyroid cancer	0.000889	0.000889	CcSEcCtD
Gadoversetamide—Palpitations—Epirubicin—thyroid cancer	0.000883	0.000883	CcSEcCtD
Gadoversetamide—Loss of consciousness—Epirubicin—thyroid cancer	0.000878	0.000878	CcSEcCtD
Gadoversetamide—Cough—Epirubicin—thyroid cancer	0.000872	0.000872	CcSEcCtD
Gadoversetamide—Vision blurred—Doxorubicin—thyroid cancer	0.000871	0.000871	CcSEcCtD
Gadoversetamide—Convulsion—Epirubicin—thyroid cancer	0.000865	0.000865	CcSEcCtD
Gadoversetamide—Hypertension—Epirubicin—thyroid cancer	0.000862	0.000862	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000858	0.000858	CcSEcCtD
Gadoversetamide—Myalgia—Epirubicin—thyroid cancer	0.00085	0.00085	CcSEcCtD
Gadoversetamide—Chest pain—Epirubicin—thyroid cancer	0.00085	0.00085	CcSEcCtD
Gadoversetamide—Arthralgia—Epirubicin—thyroid cancer	0.00085	0.00085	CcSEcCtD
Gadoversetamide—Agitation—Doxorubicin—thyroid cancer	0.000849	0.000849	CcSEcCtD
Gadoversetamide—Anxiety—Epirubicin—thyroid cancer	0.000847	0.000847	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000845	0.000845	CcSEcCtD
Gadoversetamide—Discomfort—Epirubicin—thyroid cancer	0.00084	0.00084	CcSEcCtD
Gadoversetamide—Malaise—Doxorubicin—thyroid cancer	0.000834	0.000834	CcSEcCtD
Gadoversetamide—Dry mouth—Epirubicin—thyroid cancer	0.000832	0.000832	CcSEcCtD
Gadoversetamide—Vertigo—Doxorubicin—thyroid cancer	0.00083	0.00083	CcSEcCtD
Gadoversetamide—Syncope—Doxorubicin—thyroid cancer	0.000829	0.000829	CcSEcCtD
Gadoversetamide—Confusional state—Epirubicin—thyroid cancer	0.000822	0.000822	CcSEcCtD
Gadoversetamide—Palpitations—Doxorubicin—thyroid cancer	0.000817	0.000817	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Epirubicin—thyroid cancer	0.000815	0.000815	CcSEcCtD
Gadoversetamide—Oedema—Epirubicin—thyroid cancer	0.000815	0.000815	CcSEcCtD
Gadoversetamide—Loss of consciousness—Doxorubicin—thyroid cancer	0.000812	0.000812	CcSEcCtD
Gadoversetamide—Cough—Doxorubicin—thyroid cancer	0.000807	0.000807	CcSEcCtD
Gadoversetamide—Shock—Epirubicin—thyroid cancer	0.000802	0.000802	CcSEcCtD
Gadoversetamide—Convulsion—Doxorubicin—thyroid cancer	0.000801	0.000801	CcSEcCtD
Gadoversetamide—Nervous system disorder—Epirubicin—thyroid cancer	0.000799	0.000799	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Epirubicin—thyroid cancer	0.000798	0.000798	CcSEcCtD
Gadoversetamide—Hypertension—Doxorubicin—thyroid cancer	0.000798	0.000798	CcSEcCtD
Gadoversetamide—Tachycardia—Epirubicin—thyroid cancer	0.000796	0.000796	CcSEcCtD
Gadoversetamide—Skin disorder—Epirubicin—thyroid cancer	0.000792	0.000792	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Epirubicin—thyroid cancer	0.000788	0.000788	CcSEcCtD
Gadoversetamide—Arthralgia—Doxorubicin—thyroid cancer	0.000787	0.000787	CcSEcCtD
Gadoversetamide—Myalgia—Doxorubicin—thyroid cancer	0.000787	0.000787	CcSEcCtD
Gadoversetamide—Chest pain—Doxorubicin—thyroid cancer	0.000787	0.000787	CcSEcCtD
Gadoversetamide—Anxiety—Doxorubicin—thyroid cancer	0.000784	0.000784	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000781	0.000781	CcSEcCtD
Gadoversetamide—Discomfort—Doxorubicin—thyroid cancer	0.000777	0.000777	CcSEcCtD
Gadoversetamide—Anorexia—Epirubicin—thyroid cancer	0.000777	0.000777	CcSEcCtD
Gadoversetamide—Dry mouth—Doxorubicin—thyroid cancer	0.00077	0.00077	CcSEcCtD
Gadoversetamide—Hypotension—Epirubicin—thyroid cancer	0.000762	0.000762	CcSEcCtD
Gadoversetamide—Confusional state—Doxorubicin—thyroid cancer	0.000761	0.000761	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000754	0.000754	CcSEcCtD
Gadoversetamide—Oedema—Doxorubicin—thyroid cancer	0.000754	0.000754	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000743	0.000743	CcSEcCtD
Gadoversetamide—Shock—Doxorubicin—thyroid cancer	0.000742	0.000742	CcSEcCtD
Gadoversetamide—Nervous system disorder—Doxorubicin—thyroid cancer	0.00074	0.00074	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000739	0.000739	CcSEcCtD
Gadoversetamide—Insomnia—Epirubicin—thyroid cancer	0.000737	0.000737	CcSEcCtD
Gadoversetamide—Tachycardia—Doxorubicin—thyroid cancer	0.000736	0.000736	CcSEcCtD
Gadoversetamide—Skin disorder—Doxorubicin—thyroid cancer	0.000733	0.000733	CcSEcCtD
Gadoversetamide—Paraesthesia—Epirubicin—thyroid cancer	0.000732	0.000732	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000729	0.000729	CcSEcCtD
Gadoversetamide—Dyspnoea—Epirubicin—thyroid cancer	0.000727	0.000727	CcSEcCtD
Gadoversetamide—Somnolence—Epirubicin—thyroid cancer	0.000725	0.000725	CcSEcCtD
Gadoversetamide—Anorexia—Doxorubicin—thyroid cancer	0.000719	0.000719	CcSEcCtD
Gadoversetamide—Dyspepsia—Epirubicin—thyroid cancer	0.000718	0.000718	CcSEcCtD
Gadoversetamide—Decreased appetite—Epirubicin—thyroid cancer	0.000709	0.000709	CcSEcCtD
Gadoversetamide—Hypotension—Doxorubicin—thyroid cancer	0.000705	0.000705	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000704	0.000704	CcSEcCtD
Gadoversetamide—Fatigue—Epirubicin—thyroid cancer	0.000703	0.000703	CcSEcCtD
Gadoversetamide—Pain—Epirubicin—thyroid cancer	0.000697	0.000697	CcSEcCtD
Gadoversetamide—Constipation—Epirubicin—thyroid cancer	0.000697	0.000697	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000687	0.000687	CcSEcCtD
Gadoversetamide—Insomnia—Doxorubicin—thyroid cancer	0.000682	0.000682	CcSEcCtD
Gadoversetamide—Paraesthesia—Doxorubicin—thyroid cancer	0.000677	0.000677	CcSEcCtD
Gadoversetamide—Dyspnoea—Doxorubicin—thyroid cancer	0.000673	0.000673	CcSEcCtD
Gadoversetamide—Feeling abnormal—Epirubicin—thyroid cancer	0.000672	0.000672	CcSEcCtD
Gadoversetamide—Somnolence—Doxorubicin—thyroid cancer	0.000671	0.000671	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000667	0.000667	CcSEcCtD
Gadoversetamide—Dyspepsia—Doxorubicin—thyroid cancer	0.000664	0.000664	CcSEcCtD
Gadoversetamide—Decreased appetite—Doxorubicin—thyroid cancer	0.000656	0.000656	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000651	0.000651	CcSEcCtD
Gadoversetamide—Fatigue—Doxorubicin—thyroid cancer	0.00065	0.00065	CcSEcCtD
Gadoversetamide—Urticaria—Epirubicin—thyroid cancer	0.000648	0.000648	CcSEcCtD
Gadoversetamide—Pain—Doxorubicin—thyroid cancer	0.000645	0.000645	CcSEcCtD
Gadoversetamide—Constipation—Doxorubicin—thyroid cancer	0.000645	0.000645	CcSEcCtD
Gadoversetamide—Abdominal pain—Epirubicin—thyroid cancer	0.000644	0.000644	CcSEcCtD
Gadoversetamide—Body temperature increased—Epirubicin—thyroid cancer	0.000644	0.000644	CcSEcCtD
Gadoversetamide—Feeling abnormal—Doxorubicin—thyroid cancer	0.000622	0.000622	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000617	0.000617	CcSEcCtD
Gadoversetamide—Hypersensitivity—Epirubicin—thyroid cancer	0.000601	0.000601	CcSEcCtD
Gadoversetamide—Urticaria—Doxorubicin—thyroid cancer	0.000599	0.000599	CcSEcCtD
Gadoversetamide—Body temperature increased—Doxorubicin—thyroid cancer	0.000596	0.000596	CcSEcCtD
Gadoversetamide—Abdominal pain—Doxorubicin—thyroid cancer	0.000596	0.000596	CcSEcCtD
Gadoversetamide—Asthenia—Epirubicin—thyroid cancer	0.000585	0.000585	CcSEcCtD
Gadoversetamide—Pruritus—Epirubicin—thyroid cancer	0.000577	0.000577	CcSEcCtD
Gadoversetamide—Diarrhoea—Epirubicin—thyroid cancer	0.000558	0.000558	CcSEcCtD
Gadoversetamide—Hypersensitivity—Doxorubicin—thyroid cancer	0.000556	0.000556	CcSEcCtD
Gadoversetamide—Asthenia—Doxorubicin—thyroid cancer	0.000541	0.000541	CcSEcCtD
Gadoversetamide—Dizziness—Epirubicin—thyroid cancer	0.000539	0.000539	CcSEcCtD
Gadoversetamide—Pruritus—Doxorubicin—thyroid cancer	0.000534	0.000534	CcSEcCtD
Gadoversetamide—Vomiting—Epirubicin—thyroid cancer	0.000518	0.000518	CcSEcCtD
Gadoversetamide—Diarrhoea—Doxorubicin—thyroid cancer	0.000516	0.000516	CcSEcCtD
Gadoversetamide—Rash—Epirubicin—thyroid cancer	0.000514	0.000514	CcSEcCtD
Gadoversetamide—Dermatitis—Epirubicin—thyroid cancer	0.000514	0.000514	CcSEcCtD
Gadoversetamide—Headache—Epirubicin—thyroid cancer	0.000511	0.000511	CcSEcCtD
Gadoversetamide—Dizziness—Doxorubicin—thyroid cancer	0.000499	0.000499	CcSEcCtD
Gadoversetamide—Nausea—Epirubicin—thyroid cancer	0.000484	0.000484	CcSEcCtD
Gadoversetamide—Vomiting—Doxorubicin—thyroid cancer	0.00048	0.00048	CcSEcCtD
Gadoversetamide—Rash—Doxorubicin—thyroid cancer	0.000476	0.000476	CcSEcCtD
Gadoversetamide—Dermatitis—Doxorubicin—thyroid cancer	0.000475	0.000475	CcSEcCtD
Gadoversetamide—Headache—Doxorubicin—thyroid cancer	0.000473	0.000473	CcSEcCtD
Gadoversetamide—Nausea—Doxorubicin—thyroid cancer	0.000448	0.000448	CcSEcCtD
